Selected article for: "angiotensin receptor and effective treatment"

Author: Mukherjee, Shreya; Pahan, Kalipada
Title: Is COVID-19 Gender-sensitive?
  • Cord-id: csc0as3i
  • Document date: 2021_1_6
  • ID: csc0as3i
    Snippet: While clinical characteristics exhibit that susceptibility to COVID-19 infection is equally likely between males and females, clinical outcomes show that males experience both a higher severity and fatality for COVID-19 infection than females. This review examines the evidence for these sex and gender differences and aims to illustrate possible mechanisms behind such sensitivity. Successful entry of SARS-CoV-2 into the body is dependent on the angiotensin-converting enzyme 2 (ACE2) receptor and
    Document: While clinical characteristics exhibit that susceptibility to COVID-19 infection is equally likely between males and females, clinical outcomes show that males experience both a higher severity and fatality for COVID-19 infection than females. This review examines the evidence for these sex and gender differences and aims to illustrate possible mechanisms behind such sensitivity. Successful entry of SARS-CoV-2 into the body is dependent on the angiotensin-converting enzyme 2 (ACE2) receptor and the transmembrane protease serine 2 (TMPRSS2). Thus, sex-based differences in the expression of the ACE2 receptor and TMPRSS2 may explain the disparities in COVID-19 severity and fatality. Furthermore, these disparities may also be attributed to sex-based difference in immunological responses. Finally, the differences in clinical outcomes of COVID-19 infections between men and women may be due to gendered differences in behaviors, such as smoking, and prevalence to comorbidities. An understanding of the sex and gender sensitivities of COVID-19 infection is a necessary component towards the creation of effective treatment options and therapies for the virus. [Figure: see text]

    Search related documents:
    Co phrase search for related documents
    • absolute number and acute respiratory failure: 1, 2, 3
    • absolute number and lung disease: 1
    • activation high expression and lung disease: 1
    • activity expression and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activity expression and acute respiratory failure: 1, 2, 3
    • activity expression and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activity expression and adipose tissue kidney: 1, 2
    • activity expression and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and additional rationale: 1
    • acute ards respiratory distress syndrome and additional research: 1
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lombardy region: 1, 2
    • acute ards respiratory distress syndrome and low severity: 1, 2, 3
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and additional rationale: 1
    • acute respiratory failure and low severity: 1
    • acute respiratory failure and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional research and lombardy region: 1
    • additional research and lung disease: 1, 2, 3, 4, 5